Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics Q3 revenue up 13.1% to $2.82 billion; adjusted EPS outlook raised

Positive Impact 4 of 5 earnings Written later

Quest Diagnostics reported third-quarter 2025 revenue of $2.82 billion, up 13.1% from a year earlier, and reported diluted EPS of $2.16, up 8.5%. The company raised its full-year 2025 revenue and adjusted diluted EPS guidance, but its reported diluted EPS range was lowered at both ends.

Key points

  • Q3 2025 net revenues of $2.82 billion, up 13.1%, including 6.8% organic growth; adjusted diluted EPS of $2.60, up 13.0%
  • Full-year 2025 net revenue guidance raised to $10.96 billion to $11.00 billion from $10.80 billion to $10.92 billion
  • Full-year reported diluted EPS guidance now $8.58 to $8.66, versus $8.60 to $8.80 previously; adjusted diluted EPS guidance raised to $9.76 to $9.84 from $9.63 to $9.83
  • Agreement with Corewell Health to form a lab services joint venture in Michigan; Co-Lab Solutions annual revenues expected to reach about $1 billion next year

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECOct 21, 2025, 6:50 AM ET
Accession number0001022079-25-000219

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.